OnCo
technologiesTechnologyEstablished

Decentralised and hybrid clinical trials

Running parts of a trial at home or locally, with telehealth, home nursing, and remote monitoring, so patients far from big centres can take part.

Accelerated by the pandemic and FDA guidance (2023-24), decentralised elements include telehealth visits, home infusion or blood draws, local imaging and labs, direct-to-patient drug shipping, and wearables. Vendors: Science 37 (acquired by eMed 2024), Medable, THREAD, Lightship, Walgreens/CVS trial services (partly wound down). Oncology adoption lags other areas because of IV drugs and imaging, but hybrid designs (local labs, remote consent) are common.

Generic schematic · not to scale · placeholder for the ai computation front
Flagged finding · Neural network

How it works

Decentralised trials combine remote consent and data capture, mobile nursing networks, and local investigator sites coordinated through a central protocol.

Strengths
  • Access and diversity
  • Retention
Limitations
  • IV regimens and imaging need sites
  • Data quality and oversight
  • Vendor consolidation

Key papers

1top

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Decentralised and hybrid clinical trials" OR ABSTRACT:"Decentralised and hybrid clinical trials") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Decentralised and hybrid clinical trials, not a curated reading list.

Connected

9top